<DOC>
	<DOC>NCT00063479</DOC>
	<brief_summary>The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.</brief_summary>
	<brief_title>Bisphosphonate Treatment of Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Male or Female children between 3 months and 17 years old OI type I, III or IV Exclusion Deformity or abnormality which would prevent spine bone density from being done Any surgical bonelengthening procedure Any kidney diseases or abnormalities Low calcium or vitamin D levels in the blood Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Osteogenesis Imperfecta</keyword>
	<keyword>OI</keyword>
	<keyword>bone markers</keyword>
	<keyword>fracture</keyword>
	<keyword>bone loss</keyword>
	<keyword>pediatric</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>brittle bone disease</keyword>
	<keyword>pamidronate</keyword>
</DOC>